Ascendis Pharma is a pharmaceutical company focused on developing innovative therapies to address unmet medical needs, particularly in the areas of endocrinology and oncology. The company utilizes its proprietary TransCon technology platform to develop best-in-class therapies, with a strong emphasis on patient care, scientific innovation, and sustainability. Ascendis Pharma's pipeline includes TransCon PTH and TransCon CNP for endocrinology rare diseases, as well as oncology candidates such as TransCon TLR7/8 Agonist. Committed to making a meaningful difference in the lives of patients, caregivers, physicians, and employees, Ascendis Pharma is guided by its core values and driven by its mission to impact patient lives worldwide.